Skip to content
Screener

Lucid Diagnostics LUCD Q3 2026 earnings

Reported November 12, 2026 · Before market open

Revenue$1.2MMiss by $428.1K
EPS-$0.06Miss by $0.00
Revenue estimate$1.6M
EPS estimate-$0.06
“This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”
Lishan Aklog

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$1.2M-0.7%
Gross profit-$201.0K—
Operating income-$12.3M-4.4%
Net income-$6.7M+35.8%

Balance sheet

See full
Cash & equivalents$18.0M-62.0%
Total debt$1.2M-41.7%
Total equity$5.9M-77.0%
Total assets$27.9M-47.6%

Cash flow

See full
Operating cash flow-$15.6M-42.8%
CapEx$17.0K—
Free cash flow-$15.6M—

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$79.72M-41.9%
Enterprise value$62.92M-31.5%
P/S14.7×-16.5×

Profitability

See full
Operating margin-941.7%-113pp
Net margin-892.8%-186pp

Returns & leverage

See full
Return on equity-305.6%-22.0pp
Debt / equity0.2×+0.1×
Current ratio1.2×-0.7×

FAQ

When did Lucid Diagnostics report Q3 2026 earnings?
Lucid Diagnostics (LUCD) reported Q3 2026 earnings on November 12, 2026 before market open.
What were Lucid Diagnostics's Q3 2026 revenue and EPS?
Lucid Diagnostics reported revenue of $1.2M and eps of $-0.06 for Q3 2026.
Did Lucid Diagnostics beat estimates in Q3 2026?
Revenue missed the consensus estimate of $1.6M by $428.1K. EPS missed the consensus estimate of $-0.06 by $0.00.
How did Lucid Diagnostics's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 0.7% from $1.2M a year earlier and eps grew 40.0% from $-0.10.
Where can I find Lucid Diagnostics's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001493152-26-051207) and the 10-Q periodic report (0001437749-26-036390) directly on SEC EDGAR. The filing index links above go to sec.gov.